EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?

Rahul S Dalal iD, Jessica R Allegretti iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad309 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Rahul S Dalal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsPiperidinesHumansBiological FactorsPyrimidines

Substanzen

Biological ProductstofacitinibBiological FactorsPyrimidinesPiperidines

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Rahul S Dalal, Jessica R Allegretti

Zitieren

APA

Dalal, R. S., & Allegretti, J. R. (2024). Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad309

Vancouver

Dalal RS, Allegretti JR. Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad309

BibTeX
@article{Dalal2024,
  author = {Dalal, Rahul S and Allegretti, Jessica R},
  title = {Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad309}
}
Kostenlos starten →